Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Retrospective evaluation of R-EPOCH in the frontline treatment of adult patients with PTLD after solid organ transplant. Local targets link to admitted publications; unresolved targets remain external evidence.
Incidence and outcomes of post-transplant lymphoproliferative disease after 5365 solid-organ transplants over a 20-year period at two UK transplant centres
10.1111/bjh.18065 · 2022 · External reference
Post-transplantation lymphoproliferative disorders in adults
10.1056/nejmra1702693 · 2018 · External reference
Infectious complications and mortality in post-transplant lymphoproliferative disorder following solid organ transplantation: experiences of 10 years in a single center
10.1182/blood-2023-187969 · 2023 · External reference
Post-transplant lymphoproliferative disorder: update on treatment and novel therapies
10.1111/bjh.18763 · 2023 · External reference
The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms
10.1038/s41375-022-01620-2 · 2022 · External reference
How I treat posttransplant lymphoproliferative disorder
10.1182/blood.2023020075 · 2023 · External reference
Clinicopathologic characteristics, treatment, and outcomes of post-transplant lymphoproliferative disorders: a single-institution experience using 2017 WHO diagnostic criteria
10.1097/hs9.0000000000000640 · 2021 · External reference
Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial
10.1016/s1470-2045(11)70300-x · 2012 · External reference
Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial
10.1200/jco.2016.69.3564 · 2017 · External reference
Modified risk-stratified sequential treatment (subcutaneous rituximab with or without chemotherapy) in B-cell post-transplant lymphoproliferative disorder (PTLD) after solid organ transplantation (SOT): the prospective multicentre phase II PTLD-2 trial
10.1038/s41375-022-01667-1 · 2022 · External reference
Ibrutinib as part of risk-stratified treatment for posttransplant lymphoproliferative disorder: the phase 2 tidal trial
10.1182/blood.2024023847 · 2024 · External reference
Cancer risks in solid organ transplant recipients: results from a comprehensive analysis of 72 cohort studies
10.1080/2162402x.2020.1848068 · 2020 · External reference
Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010
10.1182/blood-2005-04-1437 · 2005 · External reference
Rituximab plus concurrent infusional epoch chemotherapy is highly effective in HIV-associated B-cell non-Hodgkin lymphoma
10.1182/blood-2009-08-231613 · 2010 · External reference
The 2016 revision of the World Health Organization classification of lymphoid neoplasms
10.1182/blood-2016-01-643569 · 2016 · External reference
Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification
10.1200/jco.2013.54.8800 · 2014 · External reference
Multicenter analysis of 80 solid organ transplantation recipients with post-transplantation lymphoproliferative disease: outcomes and prognostic factors in the modern era
10.1200/jco.2009.25.4961 · 2010 · External reference
Epstein-Barr virus–positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management.
2015 · External reference
Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients – BCSH and BTS guidelines
10.1111/j.1365-2141.2010.08161.x · 2010 · External reference
Gene expression profiling reveals clear differences between EBV-positive and EBV-negative posttransplant lymphoproliferative disorders
10.1111/ajt.12196 · 2013 · External reference
Biological difference between Epstein–Barr virus positive and negative post-transplant lymphoproliferative disorders and their clinical impact
10.3389/fonc.2020.00506 · 2020 · External reference
EBV-negative monomorphic B-cell post-transplant lymphoproliferative disorders are pathologically distinct from EBV-positive cases and frequently contain TP53 mutations
10.1038/modpathol.2016.130 · 2016 · External reference
The impact of EBV status on characteristics and outcomes of posttransplantation lymphoproliferative disorder
10.1111/ajt.13324 · 2015 · External reference
Management of patients with post-transplant lymphoproliferative disorder: the role of rituximab
10.1111/j.1432-2277.2006.00284.x · 2006 · External reference
Therapeutic options in post-transplant lymphoproliferative disorders
10.1177/2040620711412417 · 2011 · External reference
Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study
10.1182/blood-2005-01-0377 · 2006 · External reference
Effect of anti-cd 20 antibody rituximab in patients with post-transplant lymphoproliferative disorder (PTLD)
10.1111/j.1600-6143.2005.01098.x · 2005 · External reference
Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease
10.3324/haematol.11360 · 2007 · External reference
Post-transplant lymphoproliferative disorder (PTLD) in the US population with demographics, treatment characteristics, and survival analysis
2023 · External reference
Post-transplant lymphoproliferative disorder (PTLD): single institutional experience of 141 patients
10.1186/s40164-017-0087-0 · 2017 · External reference
Analysis of post-transplant lymphoproliferative disorder (PTLD) outcomes with Epstein–Barr virus (EBV) assessments—a single tertiary referral center experience and review of literature
10.3390/cancers13040899 · 2021 · External reference
Post-transplant lymphoproliferative disorder in liver transplant recipients: characteristics, management and outcome from a single-centre experience with >1000 liver transplantations
10.1155/2015/517359 · 2015 · External reference
Failure of rituximab is associated with a poor outcome in diffuse large B cell lymphoma-type post-transplant lymphoproliferative disorder
10.1111/bjh.16304 · 2020 · External reference
First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study
10.1111/ejh.12782 · 2016 · External reference
Real-world outcomes with rituximab-based therapy for posttransplant lymphoproliferative disease arising after solid organ transplant
10.1097/tp.0000000000003183 · 2020 · External reference
International Prognostic Index, type of transplant and response to rituximab are key parameters to tailor treatment in adults with CD20-positive B cell PTLD: clues from the PTLD-1 trial
10.1111/ajt.13086 · 2015 · External reference
